Neil H. Bander

Department of Urology, Weill Cornell Medical College

Affiliated withWeill Cornell Medical College

Research Area

Biography

Neil H. Bander has not added Biography.
If you are Neil H. Bander and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 2	2014

Other Publications

Article	Year
Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell line. The Prostate\| PubMed ID: 12640656	2003
Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. Journal of nuclear medicine : official publication, Society of Nuclear Medicine\| PubMed ID: 12679407	2003
Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. Cancer research\| PubMed ID: 12750292	2003
A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Molecular biology of the cell\| PubMed ID: 14528023	2003
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. The Journal of urology\| PubMed ID: 14532761	2003
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Seminars in oncology\| PubMed ID: 14571414	2003
Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. The Journal of urology\| PubMed ID: 14610416	2003
Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. The Prostate\| PubMed ID: 14716739	2004
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 15173215	2004
Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjugate chemistry\| PubMed ID: 15546182	2004
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 1... Journal of nuclear medicine : official publication, Society of Nuclear Medicine\| PubMed ID: 15809486	2005
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 15837970	2005
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane anti... Journal of nuclear medicine : official publication, Society of Nuclear Medicine\| PubMed ID: 15872360	2005
N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy. Molecular cancer therapeutics\| PubMed ID: 15897234	2005
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 16203821	2005
Antibody-based therapeutics: focus on prostate cancer. Cancer metastasis reviews\| PubMed ID: 16408160	2005
Technology insight: monoclonal antibody imaging of prostate cancer. Nature clinical practice. Urology\| PubMed ID: 16607370	2006
Clinical utility of radiolabeled monoclonal antibodies in prostate cancer. Clinical genitourinary cancer\| PubMed ID: 16729907	2006
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 17290063	2007
Active and passive immunotherapy: vaccines and antibodies. BJU international\| PubMed ID: 17441928	2007
Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2. International journal of oncology\| PubMed ID: 17912448	2007
Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem\| PubMed ID: 18613203	2008
Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surr... The Prostate\| PubMed ID: 19575420	2009
Editorial comment. The Journal of urology\| PubMed ID: 19616227	2009
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Human pathology\| PubMed ID: 19716160	2009
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab on a chip\| PubMed ID: 20024046	2010
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer\| PubMed ID: 20127956	2010
ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation. Nanomedicine (London, England)\| PubMed ID: 20394530	2010
Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity. The Prostate\| PubMed ID: 20623630	2010
89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. Journal of nuclear medicine : official publication, Society of Nuclear Medicine\| PubMed ID: 20660376	2010
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 21606347	2011
Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate. Bioconjugate chemistry\| PubMed ID: 21740058	2011
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer research\| PubMed ID: 21799031	2011
Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine\| PubMed ID: 21908391	2011
Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme. Archives of pathology & laboratory medicine\| PubMed ID: 22032578	2011
Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices. Biomedical microdevices\| PubMed ID: 22143878	2012
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc\| PubMed ID: 22460809	2012
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Science translational medicine\| PubMed ID: 22491949	2012
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PloS one\| PubMed ID: 22558290	2012
Antibody-drug conjugate technology development for hematologic disorders. Clinical advances in hematology & oncology : H&O\| PubMed ID: 23072775	2012
Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine (London, England)\| PubMed ID: 23075285	2013
Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer discovery\| PubMed ID: 23093251	2012
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 23714732	2013
Enrichment of prostate cancer cells from blood cells with a hybrid dielectrophoresis and immunocapture microfluidic system. Biomedical microdevices\| PubMed ID: 23807279	2013
Antibody-drug conjugate target selection: critical factors. Methods in molecular biology (Clifton, N.J.)\| PubMed ID: 23913139	2013
Characterization of a hybrid dielectrophoresis and immunocapture microfluidic system for cancer cell capture. Electrophoresis\| PubMed ID: 23925921	2013
Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate ... Frontiers in oncology\| PubMed ID: 23986881	2013
A prospective pilot study of (89)zr-j591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. The Journal of urology\| PubMed ID: 24135437	2014
Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica\| PubMed ID: 24304465	2013
Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow. PloS one\| PubMed ID: 24386459	2013